Along with improved supportive care and thus reduced treatment-related mortality, an increasing number of elderly patients (460 years) with haematological malignancies are now considered for high-dose therapy (HDT) supported by autologous stem cell transplantation (ASCT). ASCT is feasible in selected elderly patients with multiple myeloma and those with non-Hodgkin's lymphoma. As elderly patients have generally been excluded from randomized studies evaluating efficacy of ASCT in comparison with non-transplant approaches, limited data are available on the efficacy of ASCT in this patient population. Recent developments in supportive care including amifostine and palifermin may increase feasibility of ASCT in elderly patients. Prospective studies are needed to evaluate feasibility and efficacy of ASCT in patients over 60 years of age. Also, further studies are needed in order to decrease toxicity of high-dose regimens in this patient group where co-morbid conditions may modify the toxicity of HDT in a clinically significant manner.
Introduction
Increasing age is associated with poorer survival in patients treated with conventional chemotherapy for a variety of haematological malignancies including multiple myeloma (MM) 1, 2 and non-Hodgkin's lymphoma (NHL). 3, 4 In fact, age is among the most important prognostic factors both in International Prognostic Index scoring for histologically aggressive lymphoma and Follicular Lymphoma International Prognostic Index scoring for follicular lymphoma. Poorer prognosis may be due to either different biology of haematological diseases in the elderly, due to poorer tolerance to therapy or combination of these both.
High-dose therapy (HDT) supported by autologous stem cell transplantation (ASCT) has become a widely applied therapy in many haematological malignancies. The most common current indications for ASCT include MM and NHL, 5 whereas autoimmune diseases and AL amyloidosis represent new indications. 6 Along with developments in supportive care, morbidity and mortality associated with HDT supported by ASCT have decreased. In most recent reports, 7, 8 early treatmentrelated mortality (TRM) has been in the order of 2-3%. Consequently, ASCT is now considered as a part of treatment in an increasing number of elderly patients.
Two major questions arise in the case of ASCT in elderly patients: (1) is it feasible and (2) is it efficient? A reasonable answer to the first question can be given on the basis on published although limited data. The issue of efficacy is more difficult as elderly patients have been until now excluded from most randomized trials evaluating efficacy of ASCT when compared to conventional therapy. This review attempts to evaluate what is known of the feasibility and efficacy of ASCT in patients over 60 years of age. The review will focus on the two most common current indications, MM and NHL.
Who is elderly?
Until recently, patients over 60 years of age have been considered elderly in regard to eligibility for more intensive therapies including ASCT. Most of the randomized trials of NHL including an ASCT arm have accepted only patients less than 60 years of age, [9] [10] [11] [12] although patients up to 65 years have been included in more recent trials. 13, 14 In MM, the upper age limit in randomized trials has shifted from 60 15, 16 to 65 years. [17] [18] [19] For the purpose of this review, ASCT recipients X60 years are regarded elderly, as most randomized data on the feasibility and efficacy of ASCT in comparison to conventional therapy comes from studies performed in younger patients.
Toxicity of HDT: need for pre-evaluation Co-morbid conditions are more common in elderly patients. Owing to physiological changes associated with aging and more prevalent co-morbidities, elderly patients tend to have poorer reserves especially in regard to cardiorespiratory system. The net effect of these factors is increased toxicity of HDT.
In addition to early infectious complications also organ toxicity may occur during or after HDT. Oral and gastrointestinal mucositis is a common consequence of HDT but also pulmonary, cardiac, liver and renal toxicity is observed although less frequently. The most severe form of toxicity is called early TRM. In single centre series including patients with different diagnoses, early TRM (o100 days from ASCT) has varied from 0 to 11% in elderly patients. [20] [21] [22] [23] [24] [25] Careful medical history is important as well as evaluation of prognostic factors in a given patient in regard to eligibility to HDT protocols. In addition, adequate organ function is of importance. In case of high prior cumulative anthracycline dose or in patients with prior cardiovascular disorder, a formal assessment of cardiac function with radiocardiography or 2-D echocardiography may be useful. Although various opinions exist on the value of cardiac evaluation before HDT, [26] [27] [28] elderly patients with some risk factors for cardiac complications comprise a subgroup which might benefit from this approach. Patients with a long-term smoking history and those with a previous history of chronic obstructive pulmonary disease may benefit from the evaluation of respiratory function for the assessment of pulmonary reserves. For the assessment of adequate kidney and liver function, simple laboratory tests are usually enough.
A thorough discussion with the patient is important. Realistic aims of HDT should be discussed in comparison with other available treatment options. In addition to general procedure, most common toxicities should be discussed. It should be mentioned that HDT is clearly more toxic than conventional dose therapies and that recovery from ASCT may last up to 3-4 months in this age group. On the other hand, long-term sequels of HDT, for example, infertility and secondary malignancies are perhaps less important than in younger patients.
Experiences of ASCT in patients with MM
The median age of patients with MM is 65-70 years at diagnosis. Based on randomized studies performed in younger myeloma patients 15, 17 as well as matched-pair comparisons, 29, 30 ASCT is considered the standard care in younger myeloma patients although not all studies have confirmed the superiority of ASCT. 18 Based on a randomized French trial, 31 melphalan 200 mg/m 2 (MEL200) has become the standard high-dose regimen.
Mobilization of progenitor cells is not usually a major problem in elderly myeloma patients. 32 Low-dose cyclophosphamide (CY) plus granulocyte colony-stimulating factor (G-CSF) seem to be as effective and less toxic as a regimen for progenitor cell mobilization than intermediatedose CY. 33 No differences were observed in the median peak B-CD34 þ numbers, number of CD34 þ cells collected or in the risk of poor mobilization between patients o65 years or those with X65 years of age. 34 G-CSF alone is an alternative mobilization strategy also in elderly patients. 35 In general, randomized studies have not evaluated the efficacy of ASCT when compared to conventional therapy in elderly myeloma patients. The only exception is a French study which compared ASCT with conventional therapy in patients aged 55-65 years. 36 No difference was observed in overall survival between the treatment groups, but eventfree survival was better in the ASCT arm. Although randomized data on the superiority of ASCT is limited in elderly patients, several studies have been published on the feasibility and efficacy of ASCT in myeloma patients of more than 60 years of age. These studies are summarized in Table 1 .
Excluding the registry analysis, 37 all other studies have used a high-dose MEL regimen (100-200 mg/m 2 ). In general, the response rates have been comparable to those of younger patients. 34, 38 Some studies have suggested poorer survival in elderly patients after ASCT, 39, 40 whereas in the majority of the studies progression-free and overall survival in the elderly have been comparable to those in younger patients. 34, 37, 41, 42 Early toxicity is dependent on the MEL dose. MEL100 is well tolerated also in elderly patients. 43 The most common and dose-limiting toxic side effect of high-dose MEL is its oral and gastrointestinal toxicity. 44 This is clearly shown in the study from The Little Rock group. 35 Mucositis 4grade 2 was observed in 70% of patients over 70 years of age with MEL200 but only in 40% in patients who received MEL140. Also diarrhoea and cardiac toxicity were less common in patients who received MEL140.
High-dose MEL is feasible in selected myeloma patients up to 70 years of age, whereas limited experience is available on the safety of MEL200 in patients more than ASCT beyond age 60 E Jantunen 70 years of age. Lower MEL doses are less toxic in this patient group but are also apparently less effective.
Experiences of ASCT in patients with NHL
Although some studies have suggested survival benefit of ASCT in patients with histologically aggressive lymphomas performed after first line therapy, 12,45-47 most studies have failed to confirm this. 9, 10, [48] [49] [50] Recently, inclusion of rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) regimen 51 and dose-intensification of CHOP 52 have improved outcome in patients with diffuse large B-cell lymphoma (DLBCL), thus reducing enthusiasm for high-dose consolidation in first remission. On the other hand, the Parma study 53 has shown the superiority of ASCT when compared to DHAP (dexamethasone-cytosine arabinoside-cisplatin) in patients with chemosensitive relapse. Promising survival has been observed in randomized studies also in patients with mantle cell lymphoma 14 and those with relapsed follicular lymphoma. 54 These randomized studies have not generally included elderly NHL patients.
Mobilization of progenitor cells in NHL patients consists mainly of intermediate-dose CY or disease-specific chemotherapy followed by G-CSF. 55 Progenitor cell mobilization is unsuccessful in about 10-20% of patients with NHL. [56] [57] [58] Age per se does not seem to affect progenitor cell yield or success of mobilization in NHL patients mobilized with intermediate-dose CY plus G-CSF. 58, 59 No randomized study has evaluated the feasibility and the efficacy of ASCT in elderly lymphoma patients but several single centre experiences 22, 24, 25, [59] [60] [61] [62] [63] [64] [65] and a nationwide analysis 66 have been published. These studies are shortly summarized in Table 2 .
Early TRM seems to be in the range of 5-10% in this patient group. This may be higher than the figures in NHL patients o60 years of age. For comparison, early TRM was 3% in NHL patients o60 years of age who received ASCT in Finland (1990 Finland ( -2003 66 and 2.2% in a single centre series in NHL patients o60 years of age. 65 Survival after ASCT seems to be something than can be expected from younger patients. 64, 65 At present relapsed chemosensitive DLBCL is an indication for ASCT also in elderly patients if they are otherwise fit. Patients with relapsed histologically transformed low-grade lymphomas might also be considered for ASCT. Transplants for other indications should be preferably performed in the setting of prospective clinical trials.
ASCT seems to be feasible in selected NHL patients over 60 years of age but limited data are available in patients more than 65 years of age. Early toxicity seems to be of some concern and less toxic regimens may be needed in order to decrease treatment-related morbidity and mortality. Total body irradiation-containing regimens have been used cautiously in elderly patients in many centres (Table 2) . Instead, BEAM (carmustine-etoposide-cytarabine-melphalan), BEAC (carmustine-etoposide-cytarabine-cyclophosphamide) and CBV (cyclophosphamide-carmustineetoposide) have been used. No clear data are available on the superiority of one regimen over another.
Ways to improve outcome
There may be ways to optimize ASCT in elderly patients. Adequate patient selection in regard to both disease-and patient-related factors is important. Of procedural factors, adequate graft is important to assure rapid engraftment. Use of growth factors after stem cell infusion may be important to hasten neutrophil recovery. As mucositis is closely associated with various infections, conditioning regimens causing less mucosal damage may be preferable. Cardiovascular medication should be optimized before neutropenic sepsis ensues.
As mucositis is among the most important toxicities of HDT, several attempts have been made to reduce the incidence and severity of this important toxicity. Recently, amifostine has been shown to reduce mucosal toxicity with associated complications in myeloma patients receiving high-dose MEL. 67, 68 A human recombinant keratinocyte growth factor palifermin has reduced significantly the severity and duration of mucositis in patients with haematological malignancies receiving HDT. 69 Elderly patients receiving HDT might be optimal candidates for the use of these protective agents.
Concluding remarks
ASCT is no longer only for the youngest and the fittest. With improved supportive care and increasing experience, ASCT can be performed successfully also in selected patients over 60 years of age. Efficacy seems to be in general comparable to that observed in younger patients. Also elderly patients if they are generally fit should be included in prospective studies of ASCT. There is still need for further developments in order to decrease toxicities associated with HDT and to broaden the applicability of ASCT beyond conventional age range.
